⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTXR News
Citius Pharmaceuticals Inc. Common
Form 8-K
sec.gov
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTOR
CTXR
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
prnewswire.com
CTXR
CTOR
Form 8-K
sec.gov
CTXR
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
prnewswire.com
CTXR
CTOR
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
prnewswire.com
CTXR
CTOR
Celea Therapeutics Announces $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
businesswire.com
CTXR